All In Biotech

Drug Trial Radar · NCT07665723

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

Jul 31, 2027

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by the characterization of the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates alone and after administration of afimkibart in participants with moderately to severely active ulcerative colitis (UC).

Conditions

  • Active Ulcerative Colitis

Interventions

  • AfimkibartDrug

    Afimkibart will be administered as per the schedule defined in the protocol.

  • CaffeineDrug

    Caffeine will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.

  • WarfarinDrug

    Warfarin will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.

  • OmeprazoleDrug

    Omeprazole will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.

  • DextromethorphanDrug

    Dextromethorphan will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.

  • MidazolamDrug

    Midazolam will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.

  • Vitamin KOther

    Vitamin K will be administered orally as a rescue medication following warfarin administration per the schedule outlined in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-time Curve Up to Time t (AUC0-t [AUC last]) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
  2. Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUCinf) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
  3. Maximum Plasma Concentration (Cmax) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
  4. Time to Maximum Concentration (Tmax) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
  5. Elimination Half-life (T1/2) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
  6. Metabolite-to-parent Area Under the Curve From Time 0 (AUC0-t) Ratio for CYP Probe Substrates (Midazolam and 1-OH-Midazolam, Omeprazole and 5-OH-Omeprazole, Dextromethorphan and Dextrorphan, and Caffeine and Paraxanthine)Time frame: Up to approximately 13 weeks
  7. Metabolite-to-parent Area Under the Concentration-time Curve from Time 0 to Infinity (AUC0-inf) Ratio for CYP Probe Substrates (Midazolam and 1-OH-Midazolam, Omeprazole and 5-OH-Omeprazole, Dextromethorphan and Dextrorphan, and Caffeine and Paraxanthine)Time frame: Up to approximately 13 weeks
  8. Metabolite-to-parent Concentration of CYP Probe Substrates (Midazolam and 1-OH-Midazolam, Omeprazole and 5-OH-Omeprazole, Dextromethorphan and Dextrorphan, and Caffeine and Paraxanthine)Time frame: Up to approximately 13 weeks

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • Erick H. Alayo Medical Corporation - Gastro SB Clinic

    Chula Vista, California · Recruiting

  • Atlantic Medical Research

    Margate, Florida · Recruiting

  • Allied Biomedical Research Institute, Inc

    Miami, Florida · Recruiting

  • Gastro Health Research

    Miami, Florida · Recruiting

  • UZ Leuven Gasthuisberg

    Leuven, Belgium · Recruiting

  • AZ Delta (Campus Rumbeke)

    Roeselare, Belgium · Recruiting

  • Charite Research Organisation GmbH

    Berlin, Germany · Recruiting

  • Centrum Medyczne "Medis"

    Bydgoszcz, Poland · Recruiting

  • Amicare Sp. z o.o. S.K.

    Lodz, Poland · Recruiting

  • Medrise sp z o.o

    Lublin, Poland · Recruiting

  • Allmedica Badania Kliniczne Sp z o.o. Sp K.

    Nowy Targ, Poland · Recruiting

  • NZOZ Eskulap Pabianice

    Pabianice, Poland · Recruiting

  • SOLUMED Centrum Medyczne

    Późna, Poland · Recruiting

  • Centralny Szpital Kliniczny MSW w Warszawie

    Warsaw, Poland · Recruiting

  • WIP Warsaw IBD Point Profesor Kierkus

    Warsaw, Poland · Recruiting

  • PlanetMed sp. z o.o.

    Wroc?aw, Poland · Recruiting

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom · Recruiting

  • University College London Hospitals

    London, United Kingdom · Recruiting

  • Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.